Skip to content
value.today
Marimed Inc. logo

Marimed Inc.

MRMD
$138 Mlast known market cap, Jul 2023 — no current value
Compare
World rank
—
no current market cap
Revenue
$160 M
For year ending December-2025
Net income
$-14 M
-9.1% margin
SEC filing
Employees
—

Marimed Inc. in brief

Marimed Inc. is a listed company in the Pharmaceutical industry, based in Norwood, Massachusetts, USA. Its last known market value was $138 M (July 2023); there is no current figure. In the year to December 2025 it had sales of $160 M and a net loss of $14 M. Its largest product and service lines by sales in 2025 were Product sales - retail (56%) and Product sales - wholesale (44%).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Marimed Inc.

MariMed Inc designs, develops, operations and financing of new cannabis cultivation centers and dispensaries nationwide. The company annual revenue is 50.8 million USD, annual operating income is 15.5 million USD and total assets are 76.4 million USD as on 2020. The headquarters is in USA.

Marimed Inc. timeline

4 events, 2011–2025
  1. 2011
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2017
  4. ✎
    Renamed Marimed Inc.
    Formerly Worlds Online Inc..
  5. 2022
  6. 💰
    Record net income of $13 million
    FY2022, the highest profit of the 3 years on record.
  7. 2025
  8. 💰
    Record revenue of $160 million
    FY2025, the highest of the 8 years on record.

Events of Marimed Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$78 M$157 M$235 M$313 M2023

World rank over time

▼ down 3,105 places since 2022
2022-01-07: #16885#16,88520222022-12-25: #20324#20,32420222023-07-30: #19990#19,9902023

Rank in USA: #3,492 (Jan 2022) · #4,067 (Dec 2022) · #3,919 (Jul 2023)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
—
Price / book
—
Free cash flow yield
—
Net margin (TTM)
-9.1%
Operating margin
-1.8%
Return on equity
-29.9%
Liabilities / assets
68.0%
Net debt
$67M
Revenue growth
+1.3%
R&D / revenue
7.1%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $12M, net income $-14M$12MFY18Fiscal year ending Dec 2019: revenue $46M, net income $-81M$46MFY19Fiscal year ending Dec 2020: revenue $51M, net income $2M$51MFY20Fiscal year ending Dec 2021: revenue $121M, net income $7M$121MFY21Fiscal year ending Dec 2022: revenue $134M, net income $13M$134MFY22Fiscal year ending Dec 2023: revenue $149M, net income $-16M$149MFY23Fiscal year ending Dec 2024: revenue $158M, net income $-12M$158MFY24Fiscal year ending Dec 2025: revenue $160M, net income $-14M$160MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$160M+1.3%$-3M$-14M-9.1%
Dec 2024$158M+6.1%$3M$-12M-7.9%
Dec 2023$149M+10.9%$14M$-16M-10.8%
Dec 2022$134M+10.3%$20M$13M10.1%
Dec 2021$121M+138.6%$27M$7M5.9%
Dec 2020$51M+11.6%$15M$2M4.2%
Dec 2019$46M+284.8%$-42M$-81M-178.0%
Dec 2018$12M—$-5M$-14M-114.8%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$8M$1M$7M$-0.04—
Dec 2024$7M$12M$-5M$-0.03—
Dec 2023$8M$20M$-12M$-0.04—
Dec 2022$7M$12M$-5M$0.04—
Dec 2021$36M$18M$18M$0.02—
Dec 2020$3M$5M$-1M$0.01—
Dec 2019$-24M$10M$-34M$-0.39—
Dec 2018$-3M$9M$-12M$-0.07—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$164M
Net income, trailing 12 months
$-15M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $39M, net income $-9M$39MDec ’24Three months to Mar 2025: revenue $38M, net income $-6M$38MMar ’25Three months to Jun 2025: revenue $40M, net income $-1M$40MJun ’25Three months to Sep 2025: revenue $41M, net income $-3M$41MSep ’25Three months to Dec 2025 (from the annual report): revenue $42M, net income $-5M$42MDec ’25Three months to Mar 2026: revenue $39M, net income $-4M$39MMar ’26Three months to Jun 2026: revenue $42M, net income $-4M$42MJun ’26Three months to Sep 2026: revenue $44M, net income $-4M$44MSep ’26

Latest quarter to Sep 2026: revenue $44M (+8.5% on a year earlier), net income $-4M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.

SEC filings

Official filings of Marimed Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$160 M
Operating income
$-3 M
Net income
$-14 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$203 M
Total liabilities
$138 M
Total equity
$50 M

As of December-2025

Top 1 institutional investors in Marimed Inc.#

As of Sep 30, 2026
1 institutions held 100 shares (about 0.0% of the shares outstanding) on Sep 30, 2026. Source: SEC Form 13F filings, filed through Nov 10, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 1 largest institutional investors in Marimed Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Game Plan Financial Advisors, LLC1000 (0.00%)0.00%$0 MNov 10, 2026

Insider trading at Marimed Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$13 K
5 purchases, 2 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$13 K
open market only
Insiders on file
10
since
$8 K-$23 K$0Mar 2024: bought $0 (0 trades), sold $7 K (2 trades)Mar 24Apr 2024: bought $0 (0 trades), sold $23 K (2 trades)AprDec 2025: bought $5 K (1 trades), sold $0 (0 trades)DecMay 2026: bought $8 K (4 trades), sold $0 (0 trades)May
Bought (open market)Sold (open market)Hover a month for the totals
Marimed Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Jon R. LevinePresident and CEO, Director, 10% ownerOption exercise+75,000——21.46 MForm 4
filed Jon R. LevinePresident and CEO, Director, 10% ownerShares withheld for tax-22,013$0.067$1 K21.44 MForm 4
filed Jon R. LevinePresident and CEO, Director, 10% ownerOption exercise+30,625——21.40 MForm 4
filed Timothy ShawChief Operating OfficerOption exercise+42,657——9.50 MForm 4
filed Ryan CrandallChief Commercial OfficerOption exercise+32,812——1.16 MForm 4
filed Mario PinhoChief Financial OfficerOption exercise+38,282——373,454Form 4
filed Mario PinhoChief Financial OfficerShares withheld for tax-11,236$0.060$674362,218Form 4
filed Ryan CrandallChief Commercial OfficerShares withheld for tax-9,631$0.060$5781.15 MForm 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Marimed Inc. scorecard#

Passes 5 of the 16 checks that could be worked out: strongest in growth (4 of 6), weakest in profitability (0 of 5). Fiscal year 2025.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth4 of 6
    • ✓Revenue grew in the newest year1.3%Revenue up 1.3% in fiscal 2025.
    • ✓Revenue up more than 5% a year over three years6.0%6.0% a year over the three years to fiscal 2025.
    • ✓Faster growth over three years than its peers' median6.0%6.0% a year against Pharmaceutical's median of 2.5% (65 companies).
    • ✗Earnings per share grew in the newest year-0.04 vs -0.03Diluted EPS -0.04 in fiscal 2025 against -0.03 the year before (report's currency).
    • ✗Net income higher than five years earlier-$14 M-$14 M in fiscal 2025 against $2 M in 2020.
    • ✓Revenue rose in at least four of the last five years5 of 5Revenue rose in 5 of the five years to fiscal 2025.
  • Profitability0 of 5
    • ✗Profitable in the newest year-$14 MNet income -$14 M in fiscal 2025.
    • ✗Profitable in each of the last five years2 of 5Profitable in 2 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-1.8%-1.8% against Pharmaceutical's median of 1.8% (74 companies).
    • ✗Return on equity above 15%-26.7%-26.7% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✗Operating margin wider than three years earlier-1.8%-1.8% in fiscal 2025 against 15.2% in 2022.
  • Financial health1 of 4
    • ✗Short-term assets cover short-term liabilities1.0×Current ratio 1.00 at the end of fiscal 2025.
    • ✗Debt below equity1.5×Debt to equity 1.52 at the end of fiscal 2025.
    • ✗Net debt below three years of EBITDA12.7×Net debt 12.7 times EBITDA in fiscal 2025.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✓Cash from operations positive in each of the last three years3 of 3Positive in 3 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year2.9%Diluted shares up 2.9% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Pharmaceutical, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Marimed Inc.'s statements, beside the median of Pharmaceutical.

Marimed Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-1.8%1.8%
Net margin-9.1%-1.5%
Return on equity-26.7%-0.9%
Revenue growth, 3 years a year6.1%2.5%
Revenue growth1.3%7.3%
Debt to equity1.52×0.66×

4of 9on the Piotroski tests of financial strength

  • Net loss of $14 million, the 3th loss-making year in a row.
  • Net debt is 12.7 times a year's operating earnings before depreciation.
  • Revenue has grown 11 years in a row.

Marimed Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Marimed Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue160158r149134121r5146126.13.6
Cost of revenue10295837055r20274.02.2r1.4
Gross profit5863r666466r31197.83.9r1.9r
Selling, general and administrative—————————0.8
General and administrative2626222128r9.98.8r10r2.9r0.7
Operating expenses6160r524439r1760r133.7r1.2r
Operating income−2.82.6r142027r15−42r−5.40.1r0.8r
Interest expense and finance costs7.56.99.21.72.4r9.8134.40.6r−0.3r
Net interest income—————————0.1
Share of profit of associates—————0.1−30−0.0——
Other non-operating income (expense)−8.0−6.9−21−0.9−3.0r−10−40−8.0r1.2r0.5
Income before tax−11−4.3r−6.62024r4.5−82———
Income tax3.68.29.45.916r2.10.1———
Net income including minority interests−14−12r−16147.6r2.4−82−13−1.00.3r
Minority interests' share of net income0.00.00.00.10.4r0.3−0.70.30.20.5
Net income attributable to shareholders−14−12r−16137.2r2.1−81−14−1.2−0.2r
Earnings per share, basic-0.04-0.03-0.040.040.020.01-0.39-0.07r-0.01-0.00
Earnings per share, diluted-0.04-0.03-0.040.040.020.01-0.39-0.07r-0.01-0.00
Shares, weighted average (basic)390379363338326r267209——52
Shares, weighted average (diluted)390379363380372r32420919211652
Balance sheet
Cash and cash equivalents8.97.3159.730r3.00.74.11.30.6
Short-term investments—00.10.10.3r1.41.4———
Receivables9.18.77.24.21.7r6.71.75.41.50.5
Inventory373325199.8r6.81.20.1——
Other current assets3.83.43.5r7.31.4r0.60.20.1r0.40.0r
Current assets5954514445r217.4165.0r2.4r
Property, plant and equipment8994897262r464334265.3r
Right-of-use (leased) assets7.78.79.74.95.1r5.25.8———
Goodwill2416128.12.12.1r————
Other intangible assets171917140.2r2.22.40.20.3—
Long-term investments—00.2001.21.31.7——
Total assets203207196152123r766283328.6r
Accounts payable15139.06.65.1r5.04.73.92.80.5r
Current liabilities5950r312627r233710.0r156.1r
Lease liabilities (non-current)6.67.58.54.24.6r4.85.4———
Total liabilities138129r1075749r545521219.1r
Retained earnings−128−113r−100−84−97r−105−107−26−12−11
Shareholders' equity———————6211−0.6r
Minority interests−1.9−1.8−1.7−1.5−1.6r−0.6−0.6−0.20.20.6
Total equity5059r69r5736r8.1r6.36211−0.6
Total liabilities and equity203207196152123r766283328.6
Shares outstanding39738137534133431422821117764
Cash-flow statement
Depreciation and amortization8.17.95.53.4—1.81.0r0.70.4r0.3
Share-based compensation1.91.11.06.3———5.81.10.2
Cash from operating activities7.76.87.97.336r3.4−24−2.91.8r−0.2r
Capital expenditure−1.2−12−20−12−18r−4.7−9.7−8.9−21r−3.4
Acquisitions, net of cash acquired−0.2−4.3−3.0−130—————
Cash from investing activities−1.4−17−26−26−17r−4.5−13−40−21r−3.3
Debt issued—————0.99.610——
Shares issued——————2.8326.6r0.4
Cash from financing activities−4.73.023−1.07.5r3.3334620r3.9
Change in cash1.6−7.44.9−2027r2.3−3.42.80.70.4r
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Marimed Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Product sales - retail$89 M56%
  • Product sales - wholesale$70 M44%
  • Other revenue$1 M0.8%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Events at Marimed Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 2 · Material agreement 2 · New debt 2 · Unregistered share sale 1 · Bylaws or fiscal year changed 1 · Shareholder vote 4 · Results announced 14

Marimed Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Shareholder vote8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Material agreementNew debtUnregistered share saleBylaws or fiscal year changed8-K
Results announced8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Material agreementNew debt8-K
Results announced8-K
Directors and officers8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

3 acquisitions, $19 M paid where reported

Businesses it acquired

Acquisitions by Marimed Inc.
AcquiredAcquisition dateCompletionPriceStakeSource
First State Compassion Center2025—$11 M100%Annual report
Wellness & Compassionate Care Center, Inc2024—$5 M100%Annual report
Allgreens Dispensary LLC2022—$2 M—Annual report

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

How Marimed Inc. compares in Pharmaceutical

  • Revenue$160 M · higher than 26% of 324
  • Net margin-9.1% · higher than 19% of 313
  • Revenue growth1.3% · higher than 31% of 107

Peer comparison · Pharmaceutical

CompanyMarket capP/ENet marginRev. growth
Marimed Inc.🇺🇸$138 M—-9.1%+1.3%
Eli Lilly and Company🇺🇸$1.20 T43.4×31.9%+44.7%
Johnson & Johnson🇺🇸$652.5 B40.5×16.2%+6.0%
AbbVie Inc.🇺🇸$514.0 B49.7×15.7%+8.6%
Roche Holding AG🇨🇭$370.3 B29.1×19.0%—
Merck & Co., Inc.🇺🇸$359.8 B146.7×3.6%+1.3%
Novartis AG🇨🇭$286.8 B20.5×24.7%—
Amgen Inc.🇺🇸$249.2 B26.5×24.1%+9.9%
AstraZeneca PLC🇬🇧$242.6 B23.7×17.4%+8.6%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Jul 30, 2023 (last known)
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 16, 2026

Figures from SEC filing, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Marimed Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Marimed Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Marimed Inc.? Suggest a correction